Boehringer Ingelheim

INGELHEIM, Germany, March 24, 2011 - Today Boehringer Ingelheim formally acquired Amgen's biopharmaceutical development and manufacturing facility in Fremont, California (USA).

INGELHEIM, Germany - - For Healthcare Media Outside the U.S.A., Canada, and Japan Early secondary prevention with Aggrenox(R) (extended-release dipyridamole [200 mg] plus ASA* [25mg]) is at least as effective and safe as initial treatment with ASA 100 mg alone after an ischaemic stroke or transient ischaemic attack (TIA).

INGELHEIM, Germany - For Healthcare Media Outside the U.S.A., Canada, and Japan Boehringer Ingelheim announced today that it will become the founding sponsor of the World Stroke Academy, a novel training initiative for stroke professionals being developed by the World Stroke Organization (WSO).

BRACKNELL, England - Boehringer Ingelheim maintained its growth path in 2008 too, thereby meeting the goals it had set itself.